Per Pfeiffer
A5068848511- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Cancer Treatment and Pharmacology
- Pancreatic and Hepatic Oncology Research
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal and Anal Carcinomas
- Intraperitoneal and Appendiceal Malignancies
- Colorectal Cancer Surgical Treatments
- Neuroendocrine Tumor Research Advances
- Esophageal Cancer Research and Treatment
- Frailty in Older Adults
- Cancer Immunotherapy and Biomarkers
- Nutrition and Health in Aging
- Peptidase Inhibition and Analysis
- Chemotherapy-related skin toxicity
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Radiomics and Machine Learning in Medical Imaging
- Health Systems, Economic Evaluations, Quality of Life
- Ovarian cancer diagnosis and treatment
- Pancreatitis Pathology and Treatment
- Cancer therapeutics and mechanisms
- Colorectal Cancer Screening and Detection
Odense University Hospital
2016-2025
University of Southern Denmark
2015-2024
Danish Diabetes Academy
2021-2022
Kongsberg Innovasjon (Norway)
1996-2021
GeneCare Research Institute (Japan)
2021
Onkologikoa
2006-2016
Aarhus University
1978-2013
Rigshospitalet
2007-2012
Aalborg University Hospital
1989-2012
Uppsala University Hospital
2007-2011
Patients with metastatic colorectal cancer the BRAF V600E mutation have a poor prognosis, median overall survival of 4 to 6 months after failure initial therapy. Inhibition alone has limited activity because pathway reactivation through epidermal growth factor receptor signaling.
The NORDIC-VII multicenter phase III trial investigated the efficacy of cetuximab when added to bolus fluorouracil/folinic acid and oxaliplatin (Nordic FLOX), administered continuously or intermittently, in previously untreated metastatic colorectal cancer (mCRC). influence KRAS mutation status on treatment outcome was also investigated.Patients were randomly assigned receive either standard Nordic FLOX (arm A), B), combined with intermittent C). Primary end point progression-free survival...
<h3>Importance</h3> Effective treatment options are limited for patients with advanced, metastatic esophageal cancer progressing after 2 or more lines of systemic therapy. <h3>Objective</h3> To evaluate the efficacy and safety pembrolizumab squamous cell carcinoma (ESCC) adenocarcinoma esophagus gastroesophageal junction that progressed <h3>Design, Setting, Participants</h3> This phase 2, open-label, interventional, single-arm study, KEYNOTE-180, enrolled 121 from January 12, 2016, to March...
This randomized, open-label trial compared the efficacy and safety of adjuvant
LBA4005 Background: Fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) has shown improved survival in metastatic pancreatic cancer, promising results as downstaging chemotherapy locally advanced cancer. The efficacy of neoadjuvant FOLFIRINOX patients with resectable cancer is unknown. Methods: This a randomized phase II trial included from 12 Nordic centers the period 2017-2021. Patients head were randomly assigned to receive either four cycles followed by surgery eight...
Treatment options are limited for patients with previously treated metastatic colorectal cancer (mCRC). In the LEAP-017 study, we evaluate whether lenvatinib in combination pembrolizumab improves outcomes compared standard of care (SOC) mismatch repair proficient or not microsatellite instability high (pMMR MSI-H) mCRC.
The OligoMetastatic Esophagogastric Cancer (OMEC) project aims to provide clinical practice guidelines for the definition, diagnosis, and treatment of esophagogastric oligometastatic disease (OMD).
The primary objective was to compare overall survival (OS) in patients with colorectal cancer (CRC) nonresectable liver-only metastases treated by liver transplantation or chemotherapy.CRC is the third most common worldwide. About 50% of will develop metastatic disease primarily and lung. majority receive palliative chemotherapy, a median OS trial about 2 years, less than 10% are alive at 5 years.Patients CRC underwent SECA study (n = 21). Disease-free (DFS) included were compared...
<h3>Importance</h3> The benefit of adjuvant chemotherapy after resection pancreatic cancer following neoadjuvant combination treatment with folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) is unclear. <h3>Objective</h3> To assess the association overall survival (OS) in patients FOLFIRINOX treatment. <h3>Design, Setting, Participants</h3> This international, multicenter, retrospective cohort study was conducted from January 1, 2012, to December 31, 2018. An existing...
RAS and BRAF mutations impact treatment prognosis of metastatic colorectal cancer patients (mCRC), but the knowledge is based on trial usually not representative for general population. Patient characteristics, efficacy according to KRAS, MSI status were analyzed in a prospectively collected unselected population-based cohort 798 non-resectable mCRC patients. The contained many with poor performance (39% PS 2-4) elderly (37% age>75), groups included clinical trials. Patients without...
Introduction Total mesorectal excision (TME) is the highly effective standard treatment for rectal cancer but associated with significant morbidity and may be overtreatment low-risk cancers. This study designed to determine feasibility of international recruitment in a comparing organ-saving approaches versus TME surgery. Methods analysis STAR-TREC trial multicentre randomised, three-arm parallel, phase II patients biopsy-proven adenocarcinoma rectum. The coordinated from Birmingham, UK...
Abstract Aim Organ‐saving treatment for early‐stage rectal cancer can reduce patient‐reported side effects compared to standard total mesorectal excision (TME) and preserve quality of life. An optimal strategy achieving organ preservation longer‐term oncological outcomes are unknown; thus there is a need high trials. Method Can we S ave the rectum by watchful waiting or T rans A nal surgery following (chemo) R adiotherapy versus otal early RE ctal C ancer (STAR‐TREC) an international...